Aarti Pharmalabs Ltd
Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals[1]
- Market Cap ₹ 3,956 Cr.
- Current Price ₹ 436
- High / Low ₹ 476 / 235
- Stock P/E 23.0
- Book Value ₹ 159
- Dividend Yield 0.00 %
- ROCE 15.6 %
- ROE 12.6 %
- Face Value ₹ 5.00
Pros
- Company has reduced debt.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|
| -0 | 941 | 1,511 | |
| -0 | 761 | 1,203 | |
| Operating Profit | -0 | 180 | 309 |
| OPM % | 19% | 20% | |
| -0 | 3 | 1 | |
| Interest | -0 | 11 | 20 |
| Depreciation | -0 | 37 | 56 |
| Profit before tax | -0 | 134 | 233 |
| Tax % | 20% | 26% | |
| -0 | 107 | 172 | |
| EPS in Rs | 18.95 | ||
| Dividend Payout % | -0% | 11% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 61% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 61% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 13% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|
| 0 | 0 | 45 | |
| Reserves | -0 | 1,284 | 1,393 |
| -0 | 327 | 208 | |
| 0 | 215 | 317 | |
| Total Liabilities | 0 | 1,827 | 1,963 |
| -0 | 701 | 848 | |
| CWIP | -0 | 187 | 102 |
| Investments | -0 | 40 | 43 |
| 0 | 898 | 970 | |
| Total Assets | 0 | 1,827 | 1,963 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|
| -0 | -65 | 229 | |
| -0 | -134 | -116 | |
| -0 | 255 | -157 | |
| Net Cash Flow | -0 | 56 | -43 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|
| Debtor Days | 118 | 87 | |
| Inventory Days | 359 | 280 | |
| Days Payable | 106 | 114 | |
| Cash Conversion Cycle | 371 | 253 | |
| Working Capital Days | 263 | 168 | |
| ROCE % | 18% | 16% |
Documents
Announcements
- Closure of Trading Window 28 Sep
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 15 Sep
-
Announcement under Regulation 30 (LODR)-Investor Presentation
14 Sep - Presentation to Shareholders of the Company at the 4th Annual General Meeting
- Shareholder Meeting / Postal Ballot-Outcome of AGM 14 Sep
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 4 Sep
Annual reports
Concalls
-
Sep 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
Jun 2023TranscriptNotesPPT
Business Overview:[1]
Company is a Wholly Owned Subsidiary of Aarti Industries Limited. It develops Active Pharmaceutical Ingredients, New Chemical Entities, API intermediates, Regulatory Starting Materials, Basic Starting Materials, Key Building Blocks, and Xanthine Derivatives for use in clinical testing and commercial production. It also provides stability studies, scale-up and process optimisation, process validations, and commercial manufacturing.
Company has 6 manufacturing plants and 2 R&D centres.